Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
about
The design of clinical trials to support the switching and alternation of biosimilars.Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results.The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriBiosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
P2860
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Key design considerations on c ...... lars: adalimumab as an example
@ast
Key design considerations on c ...... lars: adalimumab as an example
@en
Key design considerations on c ...... lars: adalimumab as an example
@nl
type
label
Key design considerations on c ...... lars: adalimumab as an example
@ast
Key design considerations on c ...... lars: adalimumab as an example
@en
Key design considerations on c ...... lars: adalimumab as an example
@nl
prefLabel
Key design considerations on c ...... lars: adalimumab as an example
@ast
Key design considerations on c ...... lars: adalimumab as an example
@en
Key design considerations on c ...... lars: adalimumab as an example
@nl
P2860
P1433
P1476
Key design considerations on c ...... lars: adalimumab as an example
@en
P2093
Anna La Noce
Zhihong Lai
P2860
P304
P356
10.1136/RMDOPEN-2015-000154
P407
P577
2016-01-01T00:00:00Z